{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T11:49:09Z","timestamp":1789386549783,"version":"build-2803163510"},"reference-count":18,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2016,7,19]],"date-time":"2016-07-19T00:00:00Z","timestamp":1468886400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Cynapsus Therapeutics, Inc."}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Movement Disorders"],"published-print":{"date-parts":[[2016,9]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>OFF episodes negatively impact quality of life in patients with Parkinson's disease (PD). There remains a need for an acute, effective, noninvasive treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>APL\u2010130277 is a sublingually administered apomorphine oral strip.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The authors conducted a phase 2, open\u2010label, proof\u2010of\u2010concept study. Patients presented to clinic in the morning in the practically defined OFF state and were dosed with APL\u2010130277 10 mg. Assessments of OFF or ON state and MDS\u2010UPDRS part III were conducted predose and at 15, 30, 45, 60, and 90 minutes. If a full ON was not achieved within 3 hours, the dose was increased in 5 mg increments until a full ON was achieved or to a maximum dose of 30 mg. Patients could be dosed up to two times a day over 3 days. Patients were pretreated with trimethobenzamide for 3 days, which was continued during the study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 19 patients, 15 (78.9%) achieved a full ON response. All 15 achieved a full ON response within 30 minutes and 6 of the 15 patients (40.0%) achieved a full ON response within 15 minutes. The mean (SD) duration of ON was 50 (19.4) minutes. Of the 15 patients, 9 (60.0%) remained fully ON for \u226590 minutes. There were no discontinuations as a result of an adverse event. The most common adverse events were dizziness (36.8%), somnolence (31.6%), and nausea (21.1%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This was the first study of a new sublingual apomorphine formulation in PD patients. In this open\u2010label study, APL\u2010130277 appeared to provide a convenient, rapid, and reliable method for treating OFF episodes. \u00a9 2016 The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/mds.26697","type":"journal-article","created":{"date-parts":[[2016,7,19]],"date-time":"2016-07-19T01:49:54Z","timestamp":1468892994000},"page":"1366-1372","source":"Crossref","is-referenced-by-count":73,"title":["Sublingual apomorphine (APL\u2010130277) for the acute conversion of OFF to ON in Parkinson's disease"],"prefix":"10.1002","volume":"31","author":[{"given":"Robert A.","family":"Hauser","sequence":"first","affiliation":[{"name":"University of South Florida Health Byrd Parkinson's Disease and Movement Disorders Center of Excellence Tampa Florida USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Warren","family":"Olanow","sequence":"additional","affiliation":[{"name":"Departments of Neurology and Neuroscience Mount Sinai School of Medicine New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce","family":"Dzyngel","sequence":"additional","affiliation":[{"name":"Cynapsus Therapeutics, Inc Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Bilbault","sequence":"additional","affiliation":[{"name":"Cynapsus Therapeutics, Inc Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holly","family":"Shill","sequence":"additional","affiliation":[{"name":"Barrow Neurological Institute Phoenix Arizona USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart","family":"Isaacson","sequence":"additional","affiliation":[{"name":"Parkinson's Disease and Movement Disorders Center of Boca Raton Boca Raton Florida USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan","family":"Dubow","sequence":"additional","affiliation":[{"name":"Cynapsus Therapeutics, Inc Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Agro","sequence":"additional","affiliation":[{"name":"Cynapsus Therapeutics, Inc Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,7,19]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.1090"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410250521"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.62.6.905"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.20279"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(13)70293-X"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002826-200307000-00009"},{"key":"e_1_2_8_8_1","volume-title":"Apokyn\u00ae","author":"US WorldMeds, LLC","year":"2012"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.58.9.1385"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1097\/WNF.0b013e31816d91f9"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2007.07.016"},{"key":"e_1_2_8_12_1","volume-title":"Paper presented at : 18th International Congress on Parkinson's Disease and Movement Disorders","author":"Lees A","year":"2014"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(80)90022-9"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.3109\/00207454.2010.546538"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.49.1.162"},{"key":"e_1_2_8_16_1","volume-title":"Mirapex\u00ae","author":"Boehringer Ingelheim International GmbH","year":"2013"},{"key":"e_1_2_8_17_1","volume-title":"Requip\u00ae","author":"GlaxoSmithKline","year":"2009"},{"key":"e_1_2_8_18_1","volume-title":"Requip XL\u00ae","author":"GlaxoSmithKline","year":"2008"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2014.08.010"}],"container-title":["Movement Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmds.26697","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmds.26697","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mds.26697","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T11:14:02Z","timestamp":1760958842000},"score":1,"resource":{"primary":{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/10.1002\/mds.26697"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,19]]},"references-count":18,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["10.1002\/mds.26697"],"URL":"https:\/\/doi.org\/10.1002\/mds.26697","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.726560109.793522602","asserted-by":"object"}]},"ISSN":["0885-3185","1531-8257"],"issn-type":[{"value":"0885-3185","type":"print"},{"value":"1531-8257","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,19]]}}}